Singapore markets closed

JNJ Jan 2025 190.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.53000.0000 (0.00%)
As of 12:43PM EDT. Market open.
Full screen
Previous close0.5300
Open0.5300
Bid0.0000
Ask0.0000
Strike190.00
Expiry date2025-01-17
Day's range0.5300 - 0.5300
Contract rangeN/A
Volume1
Open interest1.49k
  • Insider Monkey

    Top 12 Ultra-High Yield Dividend Stocks to Buy

    In this article, we will take a detailed look at the Top 12 Ultra-High Yield Dividend Stocks to Buy. For a quick overview of such stocks, read our article Top 5 Ultra-High Yield Dividend Stocks to Buy. Dividend investing is back in the limelight as investors seek stable income sources to protect their cash in inflation […]

  • Reuters

    US FDA mandates label updates on CAR-T cancer therapies

    The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.

  • Reuters

    J&J wins trial over Florida woman who claimed its baby powder caused her cancer

    A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019. The lawsuit was brought by family members of Patricia Matthey, a Sarasota County resident who used Johnson's baby powder daily from 1965 until August 2016, when she was diagnosed with ovarian cancer, according to her family's lawsuit. J&J's Worldwide Vice President of Litigation Erik Haas said the company was vindicated by the jury's decision.